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Heart transplantation alone has been recognized to be contraindicated when pulmonary hypertension
(PH) and elevated pulmonary vascular resistance (PVR) are irreversible, irrespective of any medical
intervention by the use of inotropic agents or pulmonary vasodilators, because such patients are at an
increased risk of post-transplantation right ventricular failure and mortality. Therefore, end-stage heart
failure patients with concomitant ﬁxed PH and irreversibly high PVR are considered to be heartelung
transplant candidates. Recently, left ventricular assist device (LVAD) therapy has been reported to
normalize PVR through persistent unloading of the left ventricle, even in patients with medically re-
fractory PH. Therefore, LVAD therapy could make such patients suitable for “heart-only” transplants,
which contributes to appropriate donor lung allocation for lung-only candidates. We review the litera-
ture regarding LVAD use for secondary PH and present a case with end-stage heart failure that could
avoid a heartelung transplant owing to LVAD therapy.
Copyright  2014, Taiwan Society of Geriatric Emergency & Critical Care Medicine. Published by Elsevier
Taiwan LLC. All rights reserved.1. Introduction
Heart transplantation alone has been recognized to be contra-
indicated when the minimum trans-pulmonary gradient is greater
than 15 mmHg or pulmonary vascular resistance is greater than
6 Wood units and irreversible, irrespective of any medical inter-
vention by the use of inotropic agents or pulmonary vasodilators;
this is because such patients are at an increased risk of post-
transplantation right ventricular failure or mortality1,2. Secondarywith any commercial entity
nuscript or any other conﬂicts
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tric Emergency & Critical Care Mepulmonary hypertension (PH) is a common consequence of end-
stage heart failure, mainly related to increased left ventricular
ﬁlling pressure. It has been reported that up to 40% of potential
heart transplant candidates develop secondary PH at the time of
evaluation3,4.
Due to high early mortality and poor outcome after “heart-only”
transplants5e7, end-stage heart failure patients concomitant with
ﬁxed PH and irreversibly high pulmonary vascular resistance (PVR)
are considered to be heartelung transplant candidates. According
to the International Society for Heart and Lung Transplantation
Registry Report in 2009, the ﬁve leading indications for heartelung
transplantation were congenital heart disease with Eisenmenger
syndrome (34.9%), idiopathic pulmonary arterial hypertension
(27.2%), cystic ﬁbrosis (14.1%), chronic obstructive pulmonary dis-
ease/emphysema (3.8%), and acquired heart disease (2.9%)8.
Therefore, nearly 3% of heartelung recipients who required
simultaneous lung and heart transplants might have medicallydicine. Published by Elsevier Taiwan LLC. All rights reserved.
Use of LVAD in Patients with End-Stage Heart Failure 43refractory PH and/or high PVR due to severe heart failure as a pri-
mary reason for their transplants. However, the world-wide num-
ber of combined heartelung transplants has remarkably reduced
and stabilized since 2001, ranging from 75 to 86 cases per year8.
This procedure involves competition with heart-only, single-lung,
and double-lung transplant candidates under circumstances of
global donor shortage.
Left ventricular assist device (LVAD) therapy has been reported
to lower pulmonary pressures through persistent unloading of the
left ventricle. Some observational studies have shown that in pa-
tients who were initially nontransplant candidates due to severe
PH secondary to heart failure, LVAD implantation decreased pul-
monary pressures, allowing patients to undergo cardiac trans-
plantation9e12. Thus, the appropriate use of LVAD would allow a
certain proportion of heartelung recipients whose primary disease
is end-stage heart failure to become only-heart candidates, thus
contributing to appropriate distribution of donor lungs to patients
who are on the lung-only waiting lists.2. Case report
A 36-year-old Japanese female with end-stage heart failure due
to dilated cardiomyopathy was listed for heart transplant in 2005.
At the time of evaluation in 2005, when under an intravenous
milrinone and dobutamine infusion, her ejection fraction,
measured by echocardiography, was 20%; her cardiac index,
1.5 L/min/m2; her serum creatinine concentration, 2.6 mg/dL; and
her PVR, 4 woods. She was successfully weaned from the milrinone
and dobutamine infusion and became ambulatory; however, she
again developed acute decompensated heart failure and was
admitted 3 months after she was discharged. In spite of the
dobutamine, milrinone, and dopamine infusion, her PVR remained
over 6 woods and her mean pulmonary artery pressure over
50 mmHg for 2 months. Reversibility of PH was assessed by
nitroglycerin and prostaglandin. The possibility of the patient
having coexisting pulmonary thromboembolism was excluded by
imaging study. The PH of the patient was not normalized by thisFig. 1. Clinical chart of the patient with end-stage heart failure and persistent pulmonary hy
DOA ¼ dopamine; DOB ¼ dobutamine; LVAD ¼ left ventricular assist device; Mean PA ¼mea
bil ¼ total bilirubin concentration.assessment. Therefore, the transplant team needed to consider
withdrawing the patient from the heart transplant waiting list and
putting her on the heartelungwaiting list, instead of the heart-only
waiting list.
After considerable discussion with the patient’s family, her
transplant team decided to perform extracorporeal pulsatile LVAD
surgery on the patient, with the hope that the LVAD would lower
her PVR. The patient’s body size was too small to undergo
implantable devise surgery. Two months after the LVAD implan-
tation, she was successfully weaned from any inotropic agents
including phosphodiesterase type 3 inhibitors with a stable PVR
between 2 and 3 Wood units. Five months after the surgery, her
PVR was stabilized between 1 and 1.5 Wood units. The patient
successfully underwent heart-only transplantation 2 years after the
LVAD surgery. The clinical course of the present case is shown in
Fig. 1.3. Discussion
Lung transplant is an effective treatment for patients with end-
stage lung disease; however, it is severely limited because of the
shortage of acceptable donor organs. Although the number of
heartelung transplantations has been small compared with single-
lung or double-lung transplantations, we could better distribute
the donor lungs if we could avoid heartelung transplantation for
patients whose primary disease is end-stage heart failure with
secondary PH.
We presented a case with end-stage heart failure concomitant
with secondary PH that was successfully treated by LVAD im-
plantation. Not only did LVAD acutely reduce PVR, but the patient
demonstrated subacute and chronic effects of LVAD on gradual
PVR reduction. The patient showed greater than 6 woods PVR for 2
months under inotropic support, irrespective of any medical
intervention prior to the surgery; however, the PVR decreased by
around 3 Wood units in the 2 months after the surgery. The PVR
even continued to reduce 5 months after the surgery, and ﬁnally
normalized. Zimpfer et al11 reported that both continuous andpertension who was treated with LVAD therapy. Cre ¼ serum creatinine concentration;
n pulmonary artery pressure; Mil ¼milrinone; PVR ¼ pulmonary vascular resistance; T-
H. Akashi et al.44pulsatile LVAD could reduce ﬁxed PH in patients with end-stage
heart failure during a 6-week period. We believe that the pre-
sent case demonstrated resolution of pulmonary hypertension
within a short-to-intermediate follow-up period, accompanied
with the serial hemodynamic examinations and clinical
presentations.
Secondary PH is the consequence of elevated left atrial ﬁlling
pressures, and LVAD therapy might reverse this process by
continuously unloading the left ventricle. A previous study
revealed that left ventricular unloading was more efﬁciently done
by continuous ﬂow devices13. Therefore, continuous ﬂow LVAD had
more potential to be highly beneﬁcial for end-stage heart failure
patients with severe secondary PH. The presented case underwent
extracorporeal pulsatile LVAD surgery due to her small body size,
but nevertheless successfully demonstrated a remarkable decrease
in PVR.
In conclusion, LVAD therapy could be considered for end-stage
heart failure patients who had medically refractory secondary PH,
in order tomake such patients suitable for “heart-only” transplants.
Avoidance of heartelung transplantation for these patients through
LVAD therapy would contribute to appropriate donor lung alloca-
tion for lung-only candidates.
References
1. Zales VR, Pahl E, Backer CL, et al. Pharmacologic reduction of pretransplantation
pulmonary vascular resistance predicts outcome after pediatric heart trans-
plantation. J Heart Lung Transplant. 1993;12:965e972.
2. Leeman M, Van Cutsem M, Vachiery JL, et al. Determinants of right ventricular
failure after heart transplantation. Acta Cardiol. 1996;51:441e449.3. Zakliczynski M, Zebik T, Maruszewski M, et al. Usefulness of pulmonary hy-
pertension reversibility test with sodium nitroprusside in stratiﬁcation of early
death risk after orthotopic heart transplantation. Transplant Proc. 2005;37:
1346e1348.
4. Klotz S, Deng MC, Hanafy D, et al. Reversible pulmonary hypertension in heart
transplant candidates e pretransplant evaluation and outcome after orthotopic
heart transplantation. Eur J Heart Fail. 2003;5:645e653.
5. Chen JM, Levin HR, Michler RE, et al. Reevaluating the signiﬁcance of pulmo-
nary hypertension before cardiac transplantation: determination of optimal
thresholds and quantiﬁcation of the effect of reversibility on perioperative
mortality. J Thorac Cardiovasc Surg. 1997;114:627e634.
6. Butler J, Stankewicz MA, Wu J, et al. Pre-transplant reversible pulmonary hy-
pertension predicts higher risk for mortality after cardiac transplantation.
J Heart Lung Transplant. 2005;24:170e177.
7. Delgado JF, Gomez-Sanchez MA, Saenz de la Calzada C, et al. Impact of mild
pulmonary hypertension on mortality and pulmonary artery pressure proﬁle
after heart transplantation. J Heart Lung Transplant. 2001;20:942e948.
8. Christie JD, Edwards LB, Aurora P, et al. The Registry of the International Society
for Heart and Lung Transplantation: Twenty-sixth Ofﬁcial Adult Lung and
HearteLung Transplantation Report e 2009. J Heart Lung Transplant. 2009;28:
1031e1049.
9. Martin J, Siegenthaler MP, Friesewinkel O, et al. Implantable left ventricular
assist device for treatment of pulmonary hypertension in candidates for
orthotopic heart transplantation e a preliminary study. Eur J Cardiothorac Surg.
2004;25:971e977.
10. Salzberg SP, Lachat ML, von Harbou K, et al. Normalization of high pulmonary
vascular resistance with LVAD support in heart transplantation candidates. Eur
J Cardiothorac Surg. 2005;27:222e225.
11. Zimpfer D, Zrunek P, Roethy W, et al. Left ventricular assist devices decrease
ﬁxed pulmonary hypertension in cardiac transplant candidates. J Thorac Car-
diovasc Surg. 2007;133:689e695.
12. Etz CD, Welp HA, Tjan TDT, et al. Medically refractory pulmonary hypertension:
treatment with nonpulsatile left ventricular assist devices. Ann Thorac Surg.
2007;83:1697e1706.
13. Haddad H, Elabbassi W, Moustafa S, et al. Left ventricular assist devices as
bridge to heart transplantation in congestive heart failure with pulmonary
hypertension. ASAIO J. 2005;51:456e460.
